FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average I	ourden									

D

D

D

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

1. Name and Addres	s of Reporting Perso	n*		S. Relationship of Reporting Person(s) to Issuer S. Relationship of Reporting Person(s) to Issuer S. Relationship of Reporting Person(s) to Issuer		ssuer										
Myer Vickesh			Editas Medicine, Inc. [EDIT]								all applicable) Director	10% C	Owner			
(Last) (First) (Middle) C/O EDITAS MEDICINE, INC.				3. Date of Earliest Transaction (Month/Day/Year) 10/17/2018								Officer (give title below) Officer Chief Technology Officer		•		
11 HURLEY ST.																
,				4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBRIDGE	MA	02141									X	Form filed by One Reporting Person Form filed by More than One Reporting				
(City)	(State)	(Zip)										Person				
	Та	ble I - No	on-Deriva	tive	Securities Acc	quired	l, Dis	sposed of,	or Be	nefici	ally	Owned				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day			Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			d 5)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code	v	Amount (A) or (D) Pric		Price	Transaction(s)			(
Common Stock 10/1			10/17/20	018		M ⁽¹⁾		3,000	A	\$0.	65	3,000	D			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

S⁽¹⁾

 $M^{(1)}$

 $S^{(1)}$

3,000

4,000

4,000

D

A

D

\$28.87(2)

\$11.21

\$29 44(3)

4,000

n

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/\)	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$0.65	10/17/2018		M ⁽¹⁾			3,000	(4)	04/29/2025	Common Stock	3,000	\$0	88,307	D	
Stock Option (right to buy)	\$11.21	10/18/2018		M ⁽¹⁾			4,000	(5)	10/29/2025	Common Stock	4,000	\$0	64,897	D	

Explanation of Responses:

Common Stock

Common Stock

Common Stock

1. The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.

10/17/2018

10/18/2018

10/18/2018

- 2. This transaction was executed in multiple trades at prices ranging from \$28.21 to \$29.08. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and the prices at which the transaction was effected.
- 3. This transaction was executed in multiple trades at prices ranging from \$29.10 to \$29.54. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and the prices at which the transaction was effected.
- 4. This option was granted on April 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on April 21, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through April 21, 2019.
- 5. This option was granted on October 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on October 27, 2016 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 27, 2019.

<u>/s/ Vickesh Myer</u> <u>10/19/2018</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.